Sign inChina's regulator granted conditional approval for savolitinib in previously treated MET-amplified gastric or GEJ adenocarcinoma, based on Phase II data showing a 32.3% response rate.
SEC filing
FDA confirmed Part 1 safety data support progression to Part 2, but U.S. initiation still awaits IND amendment review.
SEC filing
The company closed its merger with battery storage firm Nomad on July 1, 2026, changed its corporate name effective July 3, and will trade as NMAD starting July 6.
SEC filing
Tenax Therapeutics said it will present late-breaking data from its Phase 3 LEVEL trial in Munich, with topline results now expected in August 2026.
SEC filing
The amendment gives BNB Plus more time to file after all purchasers close, so long as that final closing happens by July 17, 2026.
SEC filing
The clinical-stage CRISPR company disclosed plans to list on Nasdaq as it advances its lead LDL-C program, STX-1150, through a first-in-human trial in Australia.
SEC filing
The financing, closed July 1, 2026, brings in Sixth Street and HealthCare Royalty as BridgeBio prepares three additional U.S. product launches over the next year.
SEC filing
The company amended its ATM agreement with Ladenburg Thalmann to raise the total offering ceiling from $2.3 million to $4 million as of July 2, 2026.
SEC filing
Avalon GloboCare closed a $400,000 preferred stock sale with mandatory redemption starting October 2026 and issued stock options to its interim CEO, CFO and other officers.
SEC filing
The company's press release called the financing a line of credit, but the underlying 8-K structures it as a senior secured convertible note with warrants issued to Leonite Fund I, LP.
SEC filing
The company said it drew the funds on June 29, 2026 for general purposes under a loan pact first signed in 2022 with SLR Investment Corp.
SEC filing
The financing, led by BVF Partners, is meant to fund additional patient follow-up and extend cash runway into the second quarter of 2027.
SEC filing
The French biotech priced 6.4 million ADSs at $125 each as it reported added Phase 3 ABTECT maintenance results and reaffirmed a fourth-quarter 2026 NDA target for obefazimod.
SEC filing (2)
The company reported that clinical wear data from a pre-pivotal trial support a feature meant to tell true low blood sugar apart from sensor-compression artifacts.
SEC filing (3)
The board approved one-time cash and RSU retention awards on June 30, 2026, for Ameet Mallik, Jose Carmona, and Mohamed Zaki, with vesting tied to continued employment through June 30, 2027.
SEC filing
The Inglewood, California biotechnology company reported $250,000 sold toward the offering as of a July 2, 2026 signature date, though the filing lists zero investors.
SEC filing
Elicio Therapeutics will sell 4,380,313 shares at $3.43 each to fund a planned Phase 1 trial combining ELI-002 7P with checkpoint or RAS inhibitors in metastatic pancreatic cancer.
SEC filing (2)
The company reported a senior management change effective June 30, 2026, with Caudill leaving her post as Senior Vice President and Chief Operating Officer.
SEC filing
Warrant holders agreed to exercise 2,790,340 shares at a lowered $1.60 price, generating about $4.5 million, while CEO Timothy Warbington received a $100,000 bonus.
SEC filing
A July 2, 2026 prospectus supplement shows Enanta could face $9.23 per share dilution for new investors if it sells the full $75 million at recent prices.
SEC filing
Jeff George takes the vacated audit committee seat as LENZ's board shrinks to six members, per an 8-K filed for the June 30, 2026 event.
SEC filing
Ming-Fu Chiang stepped down from NeOnc Technologies Holdings' board on June 27, 2026, and Nasim Shomali, a relative of the company's CEO, was elected to the seat days later.
SEC filing
The June 26, 2026 agreements cover Phase 3 manufacturing and clinical research for ARCT-032, with Thermo Fisher gaining commercial supply rights if the drug is approved.
SEC filing
Cingulate Inc. announced its addition to the Russell 3000E Index on July 2, 2026, and disclosed an extension of Chief Medical Officer Matthew N. Brams' employment trial period through September 30, 2026.
SEC filing
The biopharmaceutical company entered a sales agreement with Oppenheimer and Canaccord Genuity on July 2, 2026, to sell shares through an at-the-market program.
SEC filing
Enanta Pharmaceuticals entered a sales agreement allowing it to sell up to $75 million of common stock over time through Jefferies LLC.
SEC filing
Veru can sell up to $21.8 million in common stock through the two banks under a deal signed July 2, 2026, but is not required to sell any shares.
SEC filing
Goettler is stepping down to become President and CEO of Knoa Pharma LLC, according to a company filing.
SEC filing
The company disclosed the leadership change in an 8-K filed July 1, 2026, reporting an earliest event date of June 25, 2026 for the departure of the prior CMO.
SEC filing
X4 named Kelly Gold an independent director and Audit Committee member effective July 1, 2026, expanding its board to six seats.
SEC filing
Biogen disclosed preliminary estimates of in-process R&D and milestone expense for the second and third quarters of 2026, tied to collaboration payments and pending transactions.
SEC filing
The clinical stage biopharmaceutical company priced a registered direct offering, a concurrent private placement, and a warrant inducement expected to close July 1, 2026.
SEC filing (2)
Andrew Levin resigned from Climb Bio's board effective June 29, 2026, while Breanna O'Reilly, Ph.D., was elected the same day to fill a board seat.
SEC filing
The gene therapy company set final terms for a stock and pre-funded warrant sale disclosed in a June 30, 2026 SEC filing, with proceeds earmarked for its Rett syndrome program.
SEC filing (2)
The at-the-market priced deal, which sold pre-funded warrants and two series of common warrants, closed July 1, 2026, with proceeds earmarked for working capital.
SEC filing
The Eden Prairie software company registered shares for a $25 million standby equity purchase agreement and insider stock issued to two directors.
SEC filing
The biosimilar maker expanded its credit agreement to add liquidity following a recent $165 million equity raise, bringing total new capital access to $240 million.
SEC filing